FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree TREATT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Alliance reinforces REalloys position as a key leader in the U.S. rare earths supply chain DALLAS, Sept. 18, 2025 (GLOBE NEWSWIRE) — Blackboxstocks Inc. (NASDAQ: BLBX), (“Blackbox” or the “Company”), is pleased to announce that its merger target, REalloys Inc. (“REA” or “REalloys”), a vertically integrated rare earth company, today announced that it has signed a Memorandum of Understanding (“MOU”) with St George Mining Limited (“St. George”) (ASX: SGQ) to collaborate on the commercialization of rare earth minerals from their Araxá Project in Minas Gerais, Brazil. Under the alliance, REalloys and St George will enter into a long-term offtake agreement to secure REalloys access to up to 40% of Araxá’s rare earth production. The two companies will also collaborate on advanced programs to enhance processing and maximize recoveries...

Company Increases Fiscal Year 2025 Revenue Guidance to Range of $14.5 million to $15.5 million Company Issues Preliminary Fiscal Year 2026 Pro Forma Revenue Guidance of $30 million to $35 Million; a 126% increase compared to the high range of fiscal 2025 guidance Acquisition Dramatically Increases Bottling Production Capacity and is Expected to be Accretive to Earnings in Fiscal 2026 LOS ANGELES, Sept. 18, 2025 (GLOBE NEWSWIRE) — Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today announced it has entered into a definitive agreement to acquire all outstanding capital stock of Arps Dairy, Inc., an Ohio-based dairy processing company, for approximately $1.6 million in debt repayment, which the company was able to do by increasing its line...

Acquisition Through Newly Formed Wholly Owned Subsidiary, Vestand Korea Company Limited, Establishes a Strategic Bridge to Connect the Crypto Treasury Markets of the United States and Korea BREA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Vestand Incorporated (NASDAQ: VSTD) “Vestand”, or the “Company”), a global investment platform that integrates traditional real-world assets with next-generation crypto treasury strategies, today announced that it has signed a share purchase agreement to acquire 21,000 shares of AI Mindbot Equity (“AI Mindbot”) for an aggregate sum of KRW 8,499,981 or approximately USD $6,439,379 from Hyper Corporation through its wholly owned subsidiary, Vestand Korea Company Limited. Upon the closing of the transaction Vestand Korea will become the controlling shareholder of AI Mindbot and is expected to...

Enhances Electrification Capabilities with Complementary Technologies CLEVELAND, Sept. 18, 2025 (GLOBE NEWSWIRE) — Parker-Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today announced that it has completed its previously announced transaction to acquire Curtis Instruments, Inc. from Rehlko, for approximately $1 billion in cash. Curtis designs and manufactures motor speed controllers, instrumentation, power conversion and input devices that complement Parker’s capabilities in electric and hybrid vehicle motors and controls, as well as hydraulic and pneumatic technologies for the mobile machinery market. Curtis expects calendar year 2025 sales of approximately $320 million. “We welcome the Curtis team to Parker and look forward to building on our combined strengths to create accelerated growth...

VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces that it has signed an offer to acquire a well-established land surveying and mapping firm located in the state of Washington with a history of customers and past project success spanning across both Washington and Idaho. “When closed, we anticipate this acquisition will give us another location in our rapidly expanding US Drone as a Service business, establishing a strong foothold in the Northwest and unlocking significant opportunity particularly in drone-based land and marine surveys,” said Shaun Passley,...

Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company’s lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children and for which the Company is currently conducting...

FRISCO, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) — Informativ, a provider of fraud prevention, compliance, and credit technology for the automotive and consumer finance industries, today announced its acquisition of Carmatic, the intelligent Payments-as-a-Service platform built to deliver real-time, transaction-ready loan and lease payments. Informativ is backed by Capstreet, a Houston-based lower middle market private equity firm. Carmatic’s proprietary payment engine powers marketing platforms, desking tools, dealer websites, and digital retail providers to deliver accurate, fundable offers at the VIN level. By synchronizing inventory with lender programs, bank rates, and regional incentives in real time, Carmatic enables personalized deal structures designed to drive higher profitability for dealers and transparent financing options...

– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin’s potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Group as part of Roche’s Pharmaceuticals Division – SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has entered...